In Vitro Biocompatibility and Release Characteristics of Polypyrrole-bupivacaine Coatings for Neurostimulators
Lead Research Organisation:
University of East Anglia
Department Name: Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
Christopher Pickett (Principal Investigator) |
Description | New electropolmeric systems developed which can incorporate deliverable drugs. Emphasis of Follow-on-Fund grant shifted to new coatings for stents and, in conjuction with certain biomedical companies, neural stimulators. |
Exploitation Route | Patents and Know how arising in part from this study were purchased by US biomedical company in 2011. |
Sectors | Pharmaceuticals and Medical Biotechnology |
Description | Patents and know how arising in part from Follow on Fund work purchased by US biomed company. |
First Year Of Impact | 2012 |
Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
Impact Types | Economic |
Description | Chameleon Biosurfaces Ltd |
Organisation | Biotectix |
Country | United States |
Sector | Private |
PI Contribution | Synthesis and electropolymerisation of monomers |
Collaborator Contribution | Characterisation of biophysical properties. |
Impact | Patents. |
Start Year | 2006 |
Title | Coating on titanium nitride |
Description | This patent application covers applications of electropolymers for heart stimulation applications. |
IP Reference | GB1012808.0 |
Protection | Patent granted |
Year Protection Granted | 2010 |
Licensed | Commercial In Confidence |
Impact | Patent transferred to US biomedical company. Impact unknown. |
Title | POLYMER COATINGS ON MEDICAL DEVICES |
Description | This patent describes low thrombogenicity electropolymer materials including their preparation and biophysical characterisation. |
IP Reference | EP2155275 |
Protection | Patent granted |
Year Protection Granted | 2010 |
Licensed | Commercial In Confidence |
Impact | Patent transferred to US biomedical company. Commercial developments unknown. |